OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal Cancer (VELVET)
OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.
Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
Listed as NCT01802684, this PHASE2 trial focuses on Unresectable Metastatic Colorectal Cancer and remains completed. Sponsored by GERCOR - Multidisciplinary Oncology Cooperative Group, it has been updated 7 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Mar 2017 — Feb 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2017 — Mar 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
May 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GERCOR - Multidisciplinary Oncology Cooperative Group
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .